For the April-June quarter, pharma companies have posted a mixed set of numbers.
Sun Pharma, too, disappointed street with its Q1 numbers. The pharma major reported a surprise loss during the quarter under review hit by one-time charges. The company’s US business posted a 33.5 per cent decline, while India sales were up 3.2 per cent on a year-on-year (YoY) basis. Consolidated sales from operations was at Rs 7,467 crore, a decline of about 9.6 per cent over the same quarter last year. READ MORE
On the flip side, Ipca Labs reported an over three-fold jump in its consolidated net profit to Rs 445.68 crore due to robust sales. Divi's Laboratories posted an 80.61 per cent year-on-year (YoY) rise in consolidated net profit for the quarter under review.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.